Author s : RABOLU, Elena Abstract: The purpose of this paper was to implement a kinetic program intended to improve the symptomatology of the patient with spondylitis, thus increasing their quality of life. The case study has been conducted on a patient aged 49 years diagnosed with spondylitis when he was 24 years old. The therapeutic intervention consisted of applying a series of physical exercises, corrective postures and breathing exercises targeted on the achievement ankylosing spondylitis treatment the objectives relating to the patients suffering from ankylosing spondylitis 'recovery.
The analysis of results from the two tests carried out OTT and BASDAI indexes revealed that the kinetic programs are an important and instrumental component in treating the ankylosing spondylitis treatment with spondylitis, proof of which is this research demonstrating that, although it is a progressive disease, by applying a sustained therapy program, it was kept under control, the patient feeling much better from the point of view of the painful episodes, but also as a mobilization option.
To conclude, the treatment for ankylosing spondylitis supposes an active and aware participation of the patient in a program of exercises to maintain patient's muscle tone and mobility in their day to day activities. However, users may print, download, or email articles for individual use. This abstract may be abridged.
No warranty is given about the accuracy of ankylosing spondylitis treatment copy. Users should refer to the original published version of the material for the full abstract.
Important User Information: Remote access to EBSCO's databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use. However, remote access to EBSCO's databases from non-subscribing institutions is not allowed if the purpose of the use is for commercial gain through cost reduction or avoidance for a non-subscribing institution.
Aceste exemple pot conține termeni colocviali. This referral procedure relates to a request for arbitration concerning a type II variation for a new indication to include treatment of ankylosing spondylitis ASat a recommended daily dose of 90mg. Această procedură de sesizare se referă la o cerere de arbitraj privind o modificare de tip II pentru o nouă indicaţie de a include tratamentul spondilitei anchilozante SAla doza zilnică recomandată de 90 mg. The main unresolved areas of concern identified by France were concerns regarding long term safety of a daily dose of 90mg etoricoxib in the view of possible increased cardiovascular CV risk related to the use of the 90mg dose in the ankylosing spondylitis AS indication. Principalele probleme nerezolvate identificate de Franţa au fost îngrijorările legate de siguranţa pe termen lung ankylosing spondylitis treatment dozei zilnice de 90 mg de etoricoxib în legătură cu potenţialul risc cardiovascular crescut legat de utilizarea dozei de 90 mg în tratarea spondilitei anchilozante SA.